Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor is a PHASE1 clinical asset sponsored by Seattle Children's Hospital in B Cell Leukemia. SEO and diligence focus: Autologous CD19 CAR+ EGFTt + T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.